EyePoint Pharma Files Proxy Statement Amendment
Ticker: EYPT · Form: DEFA14A · Filed: May 9, 2025 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | DEFA14A |
| Filed Date | May 9, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, filing-amendment
TL;DR
EyePoint Pharma filed proxy docs, shareholders vote soon.
AI Summary
EyePoint Pharmaceuticals, Inc. filed an amendment (Amendment No. 1) to its Definitive Proxy Statement (DEFA14A) on May 9, 2025. This filing concerns the solicitation of proxies for its upcoming annual meeting. The company, formerly known as pSivida Corp. and pSivida LTD, is headquartered in Watertown, MA.
Why It Matters
This filing is crucial for shareholders as it provides updated information and materials related to the company's annual meeting, influencing their voting decisions on corporate matters.
Risk Assessment
Risk Level: low — This is a routine proxy filing, not indicating any immediate financial or operational risks.
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- pSivida Corp. (company) — Former company name
- pSivida LTD (company) — Former company name
- 20250509 (date) — Filing date
FAQ
What is the purpose of this DEFA14A filing?
This filing is an amendment to the Definitive Proxy Statement (DEFA14A) for EyePoint Pharmaceuticals, Inc., concerning the solicitation of proxies for its annual meeting.
When was this filing submitted to the SEC?
The filing was submitted on May 9, 2025.
What were EyePoint Pharmaceuticals' former company names?
EyePoint Pharmaceuticals, Inc. was formerly known as pSivida Corp. and pSivida LTD.
Where is EyePoint Pharmaceuticals, Inc. headquartered?
The company's business and mailing address is 480 Pleasant Street, Suite B300, Watertown, MA 02472.
Is this a preliminary or definitive proxy statement?
This is a Definitive Additional Material filing, an amendment to the Definitive Proxy Statement.
Filing Details
This Form DEFA14A (Form DEFA14A) was filed with the SEC on May 9, 2025 regarding EyePoint Pharmaceuticals, Inc. (EYPT).